Companies: 10,795·Total market cap: $144.5T
Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.

AUPHNASDAQHealthcare● Active
$15.66
$-0.18(-1.14%)
Market Cap$2.0B
P/E Ratio—
52W High$16.88
52W Low$7.285
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Aurinia Pharmaceuticals Inc. (AUPH) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001600620 · AUPH · NASDAQ · as of Jun 8, 2026

Filing snapshot

606
Total Filings
4
Latest Form
2026-06-08
Most Recent
2014
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001600620 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001600620-26-000017
Primary Document
auph-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001600620 · Accession 0001600620-26-000017

Latest Key Filings

6-KQuarterly Report
6-K
2020-12-30
View 6-K on SEC
8-KCurrent Report
8-K
2026-06-04Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-06-04
View
8-KCurrent Report
8-K
2026-06-04
View
8-KCurrent Report
8-K
2026-05-11
View
SC TO-T/ASC TO-T/A
SC TO-T/A
2026-05-11
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
DEF 14AProxy Statement
DEF 14A
2026-04-21
View
SC TO-TSC TO-T
SC TO-T
2026-04-13
View
8-KCurrent Report
8-K
2026-04-03
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-04-02
View
3Initial Statement of Beneficial Ownership
FORM 3
2026-04-02
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-03-25
View
8-KCurrent Report
8-K
2026-03-23
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-03-03
View
10-KAnnual Report
10-K
2026-02-26
View
Showing 1–15 of 448 filingsForm 4 / 144 hidden· 606 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001600620  |  Exchange: NASDAQ · Healthcare

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has submitted 606 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001600620, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Aurinia Pharmaceuticals Inc.'s most comprehensive regulatory disclosure. The most recent Aurinia Pharmaceuticals Inc. 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical AUPH 10-K annual reports are available from 2014 through 2026.

Investors researching Aurinia Pharmaceuticals Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
VERA SEC Filings →CLDX SEC Filings →HRMY SEC Filings →STOK SEC Filings →NUVB SEC Filings →ABCL SEC Filings →IMCR SEC Filings →BHVN SEC Filings →
→ AUPH Financials→ AUPH Earnings→ AUPH Insider Trades

Frequently Asked Questions

AUPH SEC Filings · 8 questions

Aurinia Pharmaceuticals Inc. (AUPH) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 606 filings and access original documents at no cost. Aurinia Pharmaceuticals Inc.'s CIK is 0001600620.

AUPH SEC filingsAurinia Pharmaceuticals Inc. SEC documentsfind AUPH 10-K